Combinent BioMedical Systems, a Cambridge, Mass., developer of a vaginal drug-delivery technology, raised $3 million in a first round of financing.

The round was led by Cytyc Development, a subsidiary of women’s health company Cytyc. Other investors include VIMAC Ventures and Commons Capital. Combinent is developing new combinations and formulations of drugs that can be administered via a permeable polymer ring fitted into the vagina.

A Cytyc release describes the financing here.